SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback